Systemic effects of conjugated equine estrogen vaginal cream on bone turnover markers in postmenopausal women

被引:1
作者
Luengratsameerung, S. [1 ]
Panyakhamlerd, K. [1 ]
Treratanachat, S. [2 ]
Taechakraichana, N. [1 ]
机构
[1] Chulalongkorn Univ, Reprod Med Div, Dept Obstet & Gynecol, Menopause Res Unit,Fac Med, Bangkok 10330, Thailand
[2] Chulalongkorn Univ, Div Gynecol Pathol, Dept Obstet & Gynecol, Fac Med, Bangkok 10330, Thailand
关键词
CONJUGATED EQUINE ESTROGEN; VAGINAL CREAM; BONE TURNOVER MARKERS; POSTMENOPAUSE; VULVOVAGINAL ATROPHY; HORMONE REPLACEMENT THERAPY; BIOCHEMICAL MARKERS; MINERAL DENSITY; LOCAL ESTROGEN; ESTRADIOL; EFFICACY; CALCIUM; 17-BETA-ESTRADIOL; RALOXIFENE; MANAGEMENT;
D O I
10.3109/13697137.2012.662252
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective To evaluate the systemic effect of therapy with conjugated equine estrogen (CEE) vaginal cream on bone turnover markers in postmenopausal women. Methods This study was conducted in 40 spontaneously menopausal women aged 40-60 years who complained of vulvovaginal symptoms. Subjects were instructed to self-administer 1 g CEE vaginal cream (CEE 0.625 mg) once daily for 12 weeks (continuous phase), then twice weekly for the next 12 consecutive weeks (intermittent phase). Serum levels of bone turnover markers and estradiol and the vaginal maturation index were evaluated at baseline, 12 and 24 weeks after treatment initiation. Results Levels of C-terminal cross-linked telopeptide of type I collagen (CTx) were significantly decreased at 12 weeks and 24 weeks when compared to baseline values (median (range) 0.435 (0.171-0.859) and 0.391 (0.122-0.714) vs. 0.562 (0.250-1.290) ng/ml (p < 0.001 and < 0.001), respectively), but there was no significant difference between the levels at 12 and 24 weeks. Levels of procollagen type I N-terminal propeptide (P1NP) and osteocalcin levels were significantly decreased after 24 weeks when compared to pretreatment levels (mean (standard deviation) 41.74 (11.76) vs. 50.02 (17.71) ng/ml (p = 0.002) for P1NP and 23.91 (7.11) vs. 27.54 (8.67) ng/ml (p < 0.001) for osteocalcin, respectively). Estradiol levels were significantly increased and the vaginal maturation index was significantly improved after 12 and 24 weeks when compared to baseline. Conclusions CEE vaginal cream significantly decreased the bone resorption marker (CTx) in postmenopausal women after completion of the continuous-treatment phase. There was no significant further decrease after the intermittent phase. The effects on the markers of bone formation and bone turnover (P1NP and osteocalcin) were apparent only at 24 weeks. The two treatment phases moderately increased serum estradiol levels and significantly improved the vaginal maturation index.
引用
收藏
页码:133 / 140
页数:8
相关论文
共 43 条
  • [1] Effect of three doses of conjugated estrogens/medroxyprogesteron acetate on biomarkers of bone turnover and cartilage degradation in postmenopausal women: The Pan-Asia Menopause (PAM) study
    Ausmanas, M. K.
    Hollnka, C. F.
    Ling, Y. S.
    Christiansen, C.
    [J]. CLIMACTERIC, 2007, 10 (04) : 306 - 313
  • [2] A comparative study of safety and efficacy of continuous low dose oestradiol released from a vaginal ring compared with conjugated equine oestrogen vaginal cream in the treatment of postmenopausal urogenital atrophy
    Ayton, RA
    Darling, GM
    Murkies, AL
    Farrell, EA
    Weisberg, E
    Selinus, I
    Fraser, IS
    [J]. BRITISH JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 1996, 103 (04): : 351 - 358
  • [3] Urogenital ageing: An old problem newly recognized
    Bachmann, G
    [J]. MATURITAS, 1995, 22 : S1 - S5
  • [4] Bachmann GA, 1999, TREATMENT POSTMENOPA, P195, DOI [10.1097/grf.0b013-3181809a26, DOI 10.1097/GRF.0B013-3181809A26]
  • [5] Efficacy and safety of low-dose regimens of conjugated estrogens cream administered vaginally
    Bachmann, Gloria
    Bouchard, Celine
    Hoppe, Diana
    Ranganath, Radhika
    Altomare, Corrado
    Vieweg, Alberta
    Graepel, Jay
    Helzner, Eileen
    [J]. MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2009, 16 (04): : 719 - 727
  • [6] Berman J R, 1999, Curr Opin Urol, V9, P563, DOI 10.1097/00042307-199911000-00012
  • [7] Updated practical recommendations for hormone replacement therapy in the peri- and postmenopause
    Birkhaeuser, M. H.
    Panay, N.
    Archer, D. F.
    Barlow, D.
    Burger, H.
    Gambacciani, M.
    Pinkerton, J. A.
    Goldstein, S.
    Sturdee, D. W.
    [J]. CLIMACTERIC, 2008, 11 (02) : 108 - 123
  • [8] Early response in biochemical markers predicts long-term response in bone mass during hormone replacement therapy in early postmenopausal women
    Bjarnason, NH
    Christiansen, C
    [J]. BONE, 2000, 26 (06) : 561 - 569
  • [9] Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis
    Black, Dennis M.
    Delmas, Pierre D.
    Eastell, Richard
    Reid, Ian R.
    Boonen, Steven
    Cauley, Jane A.
    Cosman, Felicia
    Lakatos, Peter
    Leung, Ping Chung
    Man, Zulema
    Mautalen, Carlos
    Mesenbrink, Peter
    Hu, Huilin
    Caminis, John
    Tong, Karen
    Rosario-Jansen, Theresa
    Krasnow, Joel
    Hue, Trisha F.
    Sellmeyer, Deborah
    Eriksen, Erik Fink
    Cummings, Steven R.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (18) : 1809 - 1822
  • [10] Management of post-menopausal vaginal atrophy and atrophic vaginitis
    Castelo-Branco, C
    Cancelo, MJ
    Villero, J
    Nohales, F
    Juliá, MD
    [J]. MATURITAS, 2005, 52 : S46 - S52